Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Sol-Gel Technologies to similar businesses based on the strength of its valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and earnings.
Earnings & Valuation
This table compares Sol-Gel Technologies and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Sol-Gel Technologies | $19.39 million | -$6.13 million | -10.51 |
| Sol-Gel Technologies Competitors | $3.55 billion | $3.17 billion | 559.01 |
Sol-Gel Technologies’ competitors have higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Analyst Recommendations
This is a summary of recent ratings for Sol-Gel Technologies and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
| Sol-Gel Technologies Competitors | 7845 | 13798 | 25820 | 1039 | 2.41 |
Sol-Gel Technologies presently has a consensus target price of $197.50, suggesting a potential upside of 259.35%. As a group, “Pharmaceuticals” companies have a potential upside of 24.06%. Given Sol-Gel Technologies’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Sol-Gel Technologies is more favorable than its competitors.
Institutional & Insider Ownership
26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Sol-Gel Technologies and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sol-Gel Technologies | -1,115.39% | -39.28% | -33.79% |
| Sol-Gel Technologies Competitors | -2,400.61% | -215.91% | -15.58% |
Summary
Sol-Gel Technologies beats its competitors on 8 of the 13 factors compared.
Sol-Gel Technologies Company Profile
Sol-Gel Technologies is an Israel-based dermatology company that develops topical treatments for skin conditions. Its proprietary technology uses silica-based microencapsulation to formulate active ingredients for topical use. The company’s products include Epsolay, a benzoyl peroxide cream approved in the United States for inflammatory lesions of rosacea, and Twyneo, a topical combination of tretinoin and benzoyl peroxide approved for acne vulgaris. Sol-Gel has pursued commercialization and licensing opportunities in the United States and other markets.
Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
